Pivotal phase 3 study of Zanubrutinib vs. Bendamustine

 Back  View
Pivotal phase 3 study of Zanubrutinib vs. Bendamustine
 IMAGE   06/2020
 View

Pivotal phase 3 study of Zanubrutinib + Rituximab vs. Bendamustine + Rituximab in previously untreated MCL patients ineligible for SCT

Rating

Rate this resource

Related resources

ESH CLL 2022 BeiGene-sponsored Virtual Satellite Symposium - Discussion and Q&A session and Closing remarks
ESH CLL 2022 BeiGene-sponsored Virtual Satellite Symposium - Discussion and Q&A session and Closing remarks
Zanubrutinib vs. Ibrutinib in R/R CLL/SLL
Zanubrutinib vs. Ibrutinib in R/R CLL/SLL
Non-inferiority study comparing Zanubrutinib vs. Bendamustine
Non-inferiority study comparing Zanubrutinib vs. Bendamustine
 Back